OSTE: Osteotech Shares Could Benefit from Improving Results and Shareholder Activism
Posted on January 25, 2010
Osteotech (OSTE - current price $3.50) is an interesting investment at current levels. The company fits all my normal criteria, namely, that recent results have been abysmal and the business is losing money. Plus the stock trades near all-time lows. On the positive side, however, OSTE has a cash-rich balance sheet with no debt, sports an EV/Sales of about 0.75, has a large revenue base, and operates in what I consider an attractive long-term market, biologic solutions for regenerative medicine. Additionally, recent communications from the company suggest that new products are gaining a bit of traction in the marketplace, revenues have stabilized, and cash losses have been eliminated (at least in the 4th quarter). Finally, recent buying of shares by activist funds and the company’s adoption of a shareholder rights plan, indicate that some sort of shareholder battle is brewing. My feeling is that if new product revenues continue to accelerate and management comes under pressure from activist investors, the shares could rise nicely this year as speculation surfaces about some sort of M&A transaction involving OSTE. Even without the M&A speculation, the shares could rise as financial results improve throughout 2010, when compared to a horrendous 2009. Solid year-over-year comps could bring in quant funds, and other mindless computer-based investment funds, into the stock.
Disclosure: Affiliates of Envoy Global Research, and its principals, own shares in OSTE. All ideas, opinions, and/or forecasts, expressed or implied herein, are for informational purposes only and should not be construed as a recommendation to invest, trade, and/or speculate in the markets. Any investments, trades, and/or speculations made in light of the ideas, opinions, and/or forecasts, expressed or implied herein, are committed at your own risk, financial or otherwise.
Comments and Discussions
The section below is intended to serve as a forum for intellectual debate about particular investment ideas or theories. Please refer to this section for any updates on a particular investment idea. If you have your own thoughts, please feel free to add them. We appreciate your feedback.Leave a Comment
If you would like to make a comment, please fill out the form below. Please note that we only require an email for editing purposes. We will NEVER publish your email or use it in any way.
Subscribe for FREE
Enter your email below to receive free research summaries.RSS Feeds:
Quick Links
Recent Comments:
Disclaimer:
This site may include market analysis and we may own shares in the stocks mentioned in our reports. All ideas, opinions, and/or forecasts, expressed or implied herein, are for informational purposes only and should not be construed as a recommendation to invest, trade, and/or speculate in the markets. Any investments, trades, and/or speculations made in light of the ideas, opinions, and/or forecasts, expressed or implied herein, are committed at your own risk, financial or otherwise.
[…] We first wrote about OSTE in January at $3.50 per share. […]